Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that management will participate in fireside chats at investor conferences on November 18 and December 2, 2026.
The Jefferies Global Healthcare Conference chat in London is scheduled for 2:30 p.m. GMT / 9:30 a.m. EST. The Evercore Healthcare Conference chat is at 10:25 a.m. EST. Live webcasts will be available on Enanta’s investor website, with replays archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that Jay R. Luly will retire as President and Chief Executive Officer by February 1, 2027.
Luly will remain a Strategic Advisor for the remainder of 2027 to support the transition after 23 years of company leadership. The board has begun a successor search considering internal and external candidates.
Enanta also appointed Tara L. Kieffer as Chief Operating Officer, a newly created role. Kieffer joined Enanta in 2020 and most recently served as Chief Product Strategy Officer. Her responsibilities will include operational execution across the business and alignment with the leadership team on company priorities.
Enanta Pharmaceuticals (ENTA) has dosed the first patient in RESOLVE, its global Phase 2b/3 trial of zelicapavir for high-risk adults with RSV. Enanta expects topline Phase 2b results in 2027. The randomized, double-blind, placebo-controlled study enrolls adult outpatients with symptoms for no more than 3 days who are at least 75 years old or have chronic obstructive pulmonary disease or congestive heart failure.
The primary endpoint is time to complete resolution of all 13 RSV symptoms; hospitalization rate is a key secondary endpoint. Phase 2b will include a minimum of 200 patients to confirm treatment effect size, while Phase 3 is expected to enroll approximately 660. In the prior Phase 2 high-risk adult trial, the corresponding risk subgroup had a 6.7-day symptom-resolution benefit versus placebo. RSV-related hospitalization rates were 0% with zelicapavir versus 5% with placebo in that trial.
Enanta Pharmaceuticals (ENTA) will present data for its investigational RSV treatment zelicapavir at IDWeek 2026 on October 22, 2026.
The poster covers a placebo-controlled Phase 2 trial in high-risk adults, including symptom resolution, hospitalization and viral load. Christopher E. Harris, M.D., will present from 12:15 PM to 1:30 PM ET in Poster Hall B-C at the Walter E. Washington Convention Center in Washington, DC.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that management will participate in two investor events in September 2026: a fireside chat at the Baird 2026 Global Healthcare Conference on September 15 at 1:25 p.m. ET, and a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 8:00 a.m. ET. Live webcasts and 30-day replays will be available via the Investors section of Enanta’s website.
Enanta Pharmaceuticals (NASDAQ: ENTA) reported fiscal Q3 2026 revenue of $14.4 million, all from royalties on AbbVie’s HCV regimen MAVYRET/MAVIRET, down from $18.3 million a year earlier. Net loss was $19.5 million, or $0.67 per diluted share, versus a loss of $18.3 million, or $0.85 per share, in Q3 2025.
Research and development expenses fell to $22.1 million from $27.2 million, and general and administrative expenses declined to $9.5 million from $10.0 million. Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026, which the company expects will fund operations into fiscal 2029, alongside retained HCV royalties.
Operationally, dosing began in LOTUS, a Phase 2b pediatric RSV trial of zelicapavir, with topline data expected in 2027, and preparations continued to initiate RESOLVE, a registrational Phase 2b/3 trial in high‑risk adults, in 4Q 2026. Enanta also advanced its immunology programs, including Phase 1 development of KIT inhibitor EDP‑978, IND‑enabling work for STAT6 inhibitor EPS‑3903, and preclinical MRGPRX2 candidates.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that its partner AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C infection in adults and children aged 3+ with or without compensated cirrhosis.
MAVIRET is now the only treatment in the EU approved for both acute and chronic HCV.
Enanta Pharmaceuticals (NASDAQ:ENTA) plans to advance zelicapavir for respiratory syncytial virus (RSV) into a registrational Phase 2b/3 adult trial starting in 4Q 2026, and a pediatric Phase 2b trial starting in 3Q 2026. Both studies will assess efficacy, safety and symptom resolution, with topline Phase 2b data expected in 2027.
Enanta Pharmaceuticals (NASDAQ:ENTA) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 a.m. ET in New York.
A live webcast and 30-day replay will be available in the Investors “Events and Presentations” section of Enanta’s website.
Summary not available.